FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078354705> ?p ?o ?g. }

• W2078354705 endingPage "2264" @default.
• W2078354705 startingPage "2257" @default.
• W2078354705 abstract "Abstract Purpose: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated. Experimental Design: We conducted a phase II trial in patients with melanoma whose tumors harbored a BRAF mutation. Patients were stratified by phosphorylated-AKT (pAKT) expression (high vs. low) and treated with selumetinib 75 mg per os twice daily. Pretreatment tumors were also analyzed for genetic changes in 230 genes of interest using an exon-capture approach. Results: The high pAKT cohort was closed after no responses were seen in the first 10 patients. The incidence of low pAKT melanoma tumors was low (∼25% of melanomas tested) and this cohort was eventually closed because of poor accrual. However, among the five patients with melanoma accrued in the low pAKT cohort, there was one partial response (PR). Two other patients had near PRs before undergoing surgical resection of residual disease (one patient) or discontinuation of treatment due to toxicity (one patient). Among the two nonresponding, low pAKT patients with melanoma, co-mutations in MAP2K1, NF1, and/or EGFR were detected. Conclusions: Tumor regression was seen in three of five patients with BRAF-mutated, low pAKT melanomas; no responses were seen in the high pAKT cohort. These results provide rationale for co-targeting MEK and PI3K/AKT in patients with BRAF mutant melanoma whose tumors express high pAKT. However, the complexity of genetic changes in melanoma indicates that additional genetic information will be needed for optimal selection of patients likely to respond to MEK inhibitors. Clin Cancer Res; 19(8); 2257–64. ©2013 AACR." @default.
• W2078354705 created "2016-06-24" @default.
• W2078354705 creator A5000845600 @default.
• W2078354705 creator A5002965160 @default.
• W2078354705 creator A5006913373 @default.
• W2078354705 creator A5015349477 @default.
• W2078354705 creator A5020106808 @default.
• W2078354705 creator A5037092952 @default.
• W2078354705 creator A5042380438 @default.
• W2078354705 creator A5048344478 @default.
• W2078354705 creator A5054656505 @default.
• W2078354705 creator A5060228803 @default.
• W2078354705 creator A5067634006 @default.
• W2078354705 creator A5083883593 @default.
• W2078354705 creator A5086473468 @default.
• W2078354705 date "2013-04-15" @default.
• W2078354705 modified "2023-10-12" @default.
• W2078354705 title "Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma" @default.
• W2078354705 cites W1970476748 @default.
• W2078354705 cites W1975852572 @default.
• W2078354705 cites W1982972087 @default.
• W2078354705 cites W1989121777 @default.
• W2078354705 cites W1989773675 @default.
• W2078354705 cites W1994193012 @default.
• W2078354705 cites W2002034430 @default.
• W2078354705 cites W2007867839 @default.
• W2078354705 cites W2009642188 @default.
• W2078354705 cites W2021341670 @default.
• W2078354705 cites W2056199226 @default.
• W2078354705 cites W2078280461 @default.
• W2078354705 cites W2080686146 @default.
• W2078354705 cites W2103441770 @default.
• W2078354705 cites W2106543129 @default.
• W2078354705 cites W2128542677 @default.
• W2078354705 cites W2130940380 @default.
• W2078354705 cites W2134471382 @default.
• W2078354705 cites W2141830999 @default.
• W2078354705 cites W2156078931 @default.
• W2078354705 cites W2163188200 @default.
• W2078354705 cites W2168143310 @default.
• W2078354705 cites W2169332496 @default.
• W2078354705 cites W2279761289 @default.
• W2078354705 cites W4233359233 @default.
• W2078354705 cites W97038594 @default.
• W2078354705 doi "https://doi.org/10.1158/1078-0432.ccr-12-3476" @default.
• W2078354705 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3932005" @default.
• W2078354705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23444215" @default.
• W2078354705 hasPublicationYear "2013" @default.
• W2078354705 type Work @default.
• W2078354705 sameAs 2078354705 @default.
• W2078354705 citedByCount "123" @default.
• W2078354705 countsByYear W20783547052012 @default.
• W2078354705 countsByYear W20783547052013 @default.
• W2078354705 countsByYear W20783547052014 @default.
• W2078354705 countsByYear W20783547052015 @default.
• W2078354705 countsByYear W20783547052016 @default.
• W2078354705 countsByYear W20783547052017 @default.
• W2078354705 countsByYear W20783547052018 @default.
• W2078354705 countsByYear W20783547052019 @default.
• W2078354705 countsByYear W20783547052020 @default.
• W2078354705 countsByYear W20783547052021 @default.
• W2078354705 countsByYear W20783547052022 @default.
• W2078354705 countsByYear W20783547052023 @default.
• W2078354705 crossrefType "journal-article" @default.
• W2078354705 hasAuthorship W2078354705A5000845600 @default.
• W2078354705 hasAuthorship W2078354705A5002965160 @default.
• W2078354705 hasAuthorship W2078354705A5006913373 @default.
• W2078354705 hasAuthorship W2078354705A5015349477 @default.
• W2078354705 hasAuthorship W2078354705A5020106808 @default.
• W2078354705 hasAuthorship W2078354705A5037092952 @default.
• W2078354705 hasAuthorship W2078354705A5042380438 @default.
• W2078354705 hasAuthorship W2078354705A5048344478 @default.
• W2078354705 hasAuthorship W2078354705A5054656505 @default.
• W2078354705 hasAuthorship W2078354705A5060228803 @default.
• W2078354705 hasAuthorship W2078354705A5067634006 @default.
• W2078354705 hasAuthorship W2078354705A5083883593 @default.
• W2078354705 hasAuthorship W2078354705A5086473468 @default.
• W2078354705 hasBestOaLocation W20783547051 @default.
• W2078354705 hasConcept C104317684 @default.
• W2078354705 hasConcept C11960822 @default.
• W2078354705 hasConcept C121608353 @default.
• W2078354705 hasConcept C126322002 @default.
• W2078354705 hasConcept C143998085 @default.
• W2078354705 hasConcept C2776087337 @default.
• W2078354705 hasConcept C2777658100 @default.
• W2078354705 hasConcept C2778715236 @default.
• W2078354705 hasConcept C2781187634 @default.
• W2078354705 hasConcept C2781249067 @default.
• W2078354705 hasConcept C501734568 @default.
• W2078354705 hasConcept C502942594 @default.
• W2078354705 hasConcept C526805850 @default.
• W2078354705 hasConcept C54355233 @default.
• W2078354705 hasConcept C57074206 @default.
• W2078354705 hasConcept C62478195 @default.
• W2078354705 hasConcept C71924100 @default.
• W2078354705 hasConcept C72563966 @default.
• W2078354705 hasConcept C75217442 @default.
• W2078354705 hasConcept C86554907 @default.

• next